Gene therapy

Illustration of a virus
#Gene therapy #Genetic diseases #Immunology / Virology & Vaccines #Virus mutation

Ancient viruses may hold key to gene therapy treatments

Scientists have unlocked key insights into virus evolution, revealing new information that could help develop treatments for a wide variety of genetic diseases.  The research focuses on a group of small, ubiquitous viruses called ‘parvoviruses’ (from the Latin word ‘parvus’ meaning ‘small’, ‘puny’ or ‘unimportant’). Read More

#Editor's Choice #News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

This week in drug discovery (28 November – 2 December)

News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer  The last seven days have seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have… Read More

#News

Dystrophin muscle protein
#FDA #Gene therapy #Muscular dystrophy #Priority Review

Gene therapy granted FDA Priority Review

The US Food and Drug Administration (FDA) has accepted Sarepta Therapeutics’ Biologics License Application (BLA) seeking accelerated approval of SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant individuals with Duchenne muscular dystrophy.   The therapy, which is being developed in partnership with Roche, has been granted Priority Review by the FDA,… Read More

#News #Regulatory

#AAV #Cell and gene therapy #Gene therapy

Accelerating gene therapy research with AAV detection kits 

PerkinElmer has launched ready-to-use adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of serious diseases.   The validated and fully automatable assays are built on PerkinElmer’s AlphaLISA technology which requires no separation and are optimised, no-wash AAV detection assays. Read More

#News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

News update available on DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  Gene therapies have made the headlines over the last week, with treatments… Read More

#News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

This week in drug discovery (21-25 November)

News round-up for 21-25 November by DDW Digital Content Editor Diana Spencer  Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. This week has also seen the first… Read More

#News

#Cell and gene therapy #FDA #Gene therapy #Haemophilia #Regulatory

FDA approves first gene therapy for haemophilia B

The US Food and Drug Administration (FDA) has approved Hemgenix (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with haemophilia B.   The drug is approved for the treatment of adults with haemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening… Read More

#News #Regulatory

Child having physiotherapy
#Gene therapy #MHRA #Rare disease #UK

Gene therapy could ‘transform prognosis’ for AADC deficiency patients 

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) has received authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK.   Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency. It is also the first marketed gene therapy directly infused into the brain. The MHRA marketing… Read More

#News #Regulatory

#Covid-19 #Covid-19 vaccine #Drug development #Drug discovery #Gene therapy #Geographic atrophy #Malaria #Monoclonal antibodies #Psychedelics #Treatment-resistant depression

This week in drug discovery (31 October – 4 November)

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer  In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Meanwhile, the quest to understand… Read More

#News

Excitatory/inhibitory neuronal reporter
#Gene delivery #Gene expression #Gene therapy #Precision medicine #Proteins

Gene expression delivery tool ‘slides’ instructions into cells

Researchers say they have successfully used a cell’s natural process for making proteins to ‘slide’ genetic instructions into a cell and produce critical proteins missing from those cells.   If further studies verify the results, this could be a new method for targeting specific cell types for a… Read More

#News #Trending News

#DNA #Gene therapy #Plasmid DNA #RNA

Yapan Bio expands to a new process development facility in India 

Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India, which has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.   The expansion includes three upstream suites (including Bio-Safety Level-2… Read More

#News

Retinitis pigmentosa
#American Academy of Ophthalmology 2022 #Dry AMD #Gene therapy #Geographic atrophy #Ophthalmology #Retinitis pigmentosa

Janssen shares ‘encouraging’ gene therapy study results

Results from Phase I/II MGT009 study into investigational gene therapy botaretigene sparoparvovec suggest sustained vision improvement in patients with X-linked retinitis pigmentosa (XLRP).  The study found treatment with botaretigene sparoparvovec had an acceptable safety profile and demonstrated encouraging improvements in retinal sensitivity, visual function and functional… Read More

#News

#Complement Therapeutics #Dry AMD #Gene therapy #Geographic atrophy #Scientific Advisory Board

Complement Therapeutics announces SAB to drive pipeline

Biotechnology company Complement Therapeutics (CTx) has formed a Clinical & Scientific Advisory Board to help accelerate the development of its pipeline of therapeutics targeting complement-mediated diseases. The company’s lead investigational product, CTx001, is a gene therapy for dry age-related macular degeneration/geographic atrophy, which is a leading cause of blindness. The… Read More

#News

Neurons
#FDA #Gene therapy #Neurodegenerative disorders

FDA approves gene therapy for rare neurological disorder

SKYSONA has become the first FDA approved therapy to slow the progression of neurologic dysfunction in boys with cerebral adrenoleukodystrophy (CALD). The US Food and Drug Administration (FDA) has granted Accelerated Approval to bluebird bio’s SKYSONA (elivaldogene autotemcel), also known as eli-cel, in boys four to 17 years of age… Read More

#News #Regulatory

RNA strand
#Gene therapy #mRNA #R&D #Research & development #RNA

New solution to boost RNA drug development

Benchling has launched its first full set of capabilities for designing, modeling, and studying both natural and chemically modified RNA in a single solution. As the biopharmaceutical industry increases its focus on developing RNA therapeutics, the new RNA solution could help R&D organisations accelerate the delivery of drug candidates. Following… Read More

#News

#Advanced Therapies #Cell and gene therapy #Events #Gene therapy #Phacilitate

What to expect from Advanced Therapies Europe 2022

The Phacilitate Advanced Therapies Europe 2022 conference will take place from 30 August to 1 September at the Royal Lancaster in London, UK. The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US. The event is tailored to a European audience… Read More

#Exclusive Content